Genomic Markers in Prostate Cancer Decision Making

Vito Cucchiara, Matthew R. Cooperberg, Marc Dall'Era, Daniel W. Lin, Francesco Montorsi, Jack A. Schalken, Christopher P Evans

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Context: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. Objective: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease. Evidence acquisition: A PubMed-based literature search was conducted up to May 2017. We selected the most recent and relevant original articles and clinical trials that have provided indispensable information to guide treatment decisions. Evidence synthesis: Genome-wide association studies have identified several genetic polymorphisms and inherited variants associated with PCa susceptibility. Moreover, the urine-based assays SelectMDx, Mi-Prostate Score, and ExoDx have provided new insights into the identification of patients who may benefit from prostate biopsy. In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy. Commercially available tools (Decipher, Oncotype DX, and Prolaris) improved PCa risk stratification, identifying men at the highest risk of adverse outcome. Furthermore, other biomarkers could assist in treatment selection in castration-resistant PCa. AR-V7 expression predicts resistance to abiraterone/enzalutamide, while poly(ADP-ribose) polymerase-1 inhibitor and platinum-based chemotherapy could be indicated in metastatic patients who are carriers of mutations in DNA mismatch repair genes. Conclusions: Introduction of genomic biomarkers has dramatically improved the detection, prognosis, and risk evaluation of PCa. Despite the progress made in discovering suitable biomarker candidates, few have been used in a clinical setting. Large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. Patient summary: Prostate cancer is a heterogeneous disease with a wide variability. Genomic biomarkers in combination with clinical and pathological variables are useful tools to reduce the number of unnecessary biopsies, stratify low-risk from high-risk tumors, and guide personalized treatment decisions. Genomic biomarkers in combination with clinical and pathological variables are useful tools to guide prostate cancer decision making.

Original languageEnglish (US)
JournalEuropean Urology
DOIs
StateAccepted/In press - Jan 1 2017

Fingerprint

Prostatic Neoplasms
Decision Making
Biomarkers
Prostate-Specific Antigen
Biopsy
Prostate
DNA Mismatch Repair
Aptitude
Genome-Wide Association Study
Castration
Genetic Polymorphisms
Therapeutics
Platinum
Early Detection of Cancer
PubMed
Neoplasms
Clinical Trials
Urine
Technology
Antigens

Keywords

  • Biomarkers
  • Cost effectiveness
  • Decision making
  • Genetic test
  • Outcome
  • Predictive
  • Prognostic
  • Prostate cancer
  • Stratification
  • Susceptibility
  • Treatment response

ASJC Scopus subject areas

  • Urology

Cite this

Cucchiara, V., Cooperberg, M. R., Dall'Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (Accepted/In press). Genomic Markers in Prostate Cancer Decision Making. European Urology. https://doi.org/10.1016/j.eururo.2017.10.036

Genomic Markers in Prostate Cancer Decision Making. / Cucchiara, Vito; Cooperberg, Matthew R.; Dall'Era, Marc; Lin, Daniel W.; Montorsi, Francesco; Schalken, Jack A.; Evans, Christopher P.

In: European Urology, 01.01.2017.

Research output: Contribution to journalArticle

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA et al. Genomic Markers in Prostate Cancer Decision Making. European Urology. 2017 Jan 1. https://doi.org/10.1016/j.eururo.2017.10.036
Cucchiara, Vito ; Cooperberg, Matthew R. ; Dall'Era, Marc ; Lin, Daniel W. ; Montorsi, Francesco ; Schalken, Jack A. ; Evans, Christopher P. / Genomic Markers in Prostate Cancer Decision Making. In: European Urology. 2017.
@article{2d3f4a54600041529c1c6516ebcaf5e1,
title = "Genomic Markers in Prostate Cancer Decision Making",
abstract = "Context: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. Objective: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease. Evidence acquisition: A PubMed-based literature search was conducted up to May 2017. We selected the most recent and relevant original articles and clinical trials that have provided indispensable information to guide treatment decisions. Evidence synthesis: Genome-wide association studies have identified several genetic polymorphisms and inherited variants associated with PCa susceptibility. Moreover, the urine-based assays SelectMDx, Mi-Prostate Score, and ExoDx have provided new insights into the identification of patients who may benefit from prostate biopsy. In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy. Commercially available tools (Decipher, Oncotype DX, and Prolaris) improved PCa risk stratification, identifying men at the highest risk of adverse outcome. Furthermore, other biomarkers could assist in treatment selection in castration-resistant PCa. AR-V7 expression predicts resistance to abiraterone/enzalutamide, while poly(ADP-ribose) polymerase-1 inhibitor and platinum-based chemotherapy could be indicated in metastatic patients who are carriers of mutations in DNA mismatch repair genes. Conclusions: Introduction of genomic biomarkers has dramatically improved the detection, prognosis, and risk evaluation of PCa. Despite the progress made in discovering suitable biomarker candidates, few have been used in a clinical setting. Large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. Patient summary: Prostate cancer is a heterogeneous disease with a wide variability. Genomic biomarkers in combination with clinical and pathological variables are useful tools to reduce the number of unnecessary biopsies, stratify low-risk from high-risk tumors, and guide personalized treatment decisions. Genomic biomarkers in combination with clinical and pathological variables are useful tools to guide prostate cancer decision making.",
keywords = "Biomarkers, Cost effectiveness, Decision making, Genetic test, Outcome, Predictive, Prognostic, Prostate cancer, Stratification, Susceptibility, Treatment response",
author = "Vito Cucchiara and Cooperberg, {Matthew R.} and Marc Dall'Era and Lin, {Daniel W.} and Francesco Montorsi and Schalken, {Jack A.} and Evans, {Christopher P}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.eururo.2017.10.036",
language = "English (US)",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

TY - JOUR

T1 - Genomic Markers in Prostate Cancer Decision Making

AU - Cucchiara, Vito

AU - Cooperberg, Matthew R.

AU - Dall'Era, Marc

AU - Lin, Daniel W.

AU - Montorsi, Francesco

AU - Schalken, Jack A.

AU - Evans, Christopher P

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Context: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. Objective: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease. Evidence acquisition: A PubMed-based literature search was conducted up to May 2017. We selected the most recent and relevant original articles and clinical trials that have provided indispensable information to guide treatment decisions. Evidence synthesis: Genome-wide association studies have identified several genetic polymorphisms and inherited variants associated with PCa susceptibility. Moreover, the urine-based assays SelectMDx, Mi-Prostate Score, and ExoDx have provided new insights into the identification of patients who may benefit from prostate biopsy. In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy. Commercially available tools (Decipher, Oncotype DX, and Prolaris) improved PCa risk stratification, identifying men at the highest risk of adverse outcome. Furthermore, other biomarkers could assist in treatment selection in castration-resistant PCa. AR-V7 expression predicts resistance to abiraterone/enzalutamide, while poly(ADP-ribose) polymerase-1 inhibitor and platinum-based chemotherapy could be indicated in metastatic patients who are carriers of mutations in DNA mismatch repair genes. Conclusions: Introduction of genomic biomarkers has dramatically improved the detection, prognosis, and risk evaluation of PCa. Despite the progress made in discovering suitable biomarker candidates, few have been used in a clinical setting. Large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. Patient summary: Prostate cancer is a heterogeneous disease with a wide variability. Genomic biomarkers in combination with clinical and pathological variables are useful tools to reduce the number of unnecessary biopsies, stratify low-risk from high-risk tumors, and guide personalized treatment decisions. Genomic biomarkers in combination with clinical and pathological variables are useful tools to guide prostate cancer decision making.

AB - Context: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. Objective: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease. Evidence acquisition: A PubMed-based literature search was conducted up to May 2017. We selected the most recent and relevant original articles and clinical trials that have provided indispensable information to guide treatment decisions. Evidence synthesis: Genome-wide association studies have identified several genetic polymorphisms and inherited variants associated with PCa susceptibility. Moreover, the urine-based assays SelectMDx, Mi-Prostate Score, and ExoDx have provided new insights into the identification of patients who may benefit from prostate biopsy. In men with previous negative pathological findings, Prostate Cancer Antigen 3 and ConfirmMDx predicted the outcome of subsequent biopsy. Commercially available tools (Decipher, Oncotype DX, and Prolaris) improved PCa risk stratification, identifying men at the highest risk of adverse outcome. Furthermore, other biomarkers could assist in treatment selection in castration-resistant PCa. AR-V7 expression predicts resistance to abiraterone/enzalutamide, while poly(ADP-ribose) polymerase-1 inhibitor and platinum-based chemotherapy could be indicated in metastatic patients who are carriers of mutations in DNA mismatch repair genes. Conclusions: Introduction of genomic biomarkers has dramatically improved the detection, prognosis, and risk evaluation of PCa. Despite the progress made in discovering suitable biomarker candidates, few have been used in a clinical setting. Large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies. Patient summary: Prostate cancer is a heterogeneous disease with a wide variability. Genomic biomarkers in combination with clinical and pathological variables are useful tools to reduce the number of unnecessary biopsies, stratify low-risk from high-risk tumors, and guide personalized treatment decisions. Genomic biomarkers in combination with clinical and pathological variables are useful tools to guide prostate cancer decision making.

KW - Biomarkers

KW - Cost effectiveness

KW - Decision making

KW - Genetic test

KW - Outcome

KW - Predictive

KW - Prognostic

KW - Prostate cancer

KW - Stratification

KW - Susceptibility

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=85033462545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033462545&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2017.10.036

DO - 10.1016/j.eururo.2017.10.036

M3 - Article

C2 - 29129398

AN - SCOPUS:85033462545

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -